Her work has focused on improving clinical trials in low and middle-income countries, including training of clinical teams, strengthening regulatory protocols, and resource sharing. In particular, she has sought to improve research on clinical trials in complex situations such as refugee camps, natural disasters, and displacement of populations. She has led on training and capacity development programmes, including one with
Palmer Masumbe Netongo, to support research within the African Coalition for Epidemic Research, Capacity, and Training. She also led on a collaborative project with the
University of Liverpool to improve the management of brain infections. In 2014, Lang helped organise a clinical trial for the drug
brincidofovir during the Ebola virus outbreak in
Liberia. She later helped the
World Health Organization evaluate the design of a clinical trial for Ebola disease therapeutics during the
2018 outbreak.
Clinical research during the 2014 Ebola outbreak Lang was part of a team of scientists at the University of Oxford developing clinical trials for therapeutics against Ebola. She advocated against
randomised controlled trials in this specific outbreak, arguing that this model was not appropriate when there was already mistrust of health systems and people were desperate to access medication. Instead the team wanted to give drugs to all Ebola patients and compare survival rates before and after the trial had started. This was met with conflicting stances from the US
FDA, however following a meeting with the WHO, the team's approach was approved. Lang took charge of liaising with regulators and the drug company in order to start the trial as quickly as possible. She also briefed US
White House officials on the progress of clinical research during the Ebola outbreak. In the end the trial took less than 4 months to be organised, compared to the average 18 months expected for this kind of trial. == Professional service ==